Cancer CDK Inhibitors Market Size, Share, Industry, Forecast and outlook (2024-2031)

Cancer CDK Inhibitors Market is segmented By  Drug Type (Palbiciclib, Ribociclib, Abemaciclib), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

Global Cancer CDK Inhibitors Market reached US$ 9.3 billion in 2023 and is expected to reach US$ 13.8 billion by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.

Cancer CDK (Cyclin-Dependent Kinase) inhibitors are a class of drugs designed to target and inhibit the activity of cyclin-dependent kinases, which are critical regulators of cell cycle progression. These inhibitors are primarily used in the treatment of various cancers, particularly those that exhibit dysregulated cell cycle control.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers & Restraints

Increasing advancement in drug development

Advancements in drug development have shown the promising potential of CDK-4/6 inhibitors in breast cancer treatment. These inhibitors have been accepted in many countries due to their therapeutic efficacy compared to conventional treatments. The FDA has approved more inhibitory drug therapies, leading to the acceptance of new technologies in the field of breast cancer treatment. For example, GI Therapeutics began clinical trials for its CDK-4/6 inhibitor, trilaciclib, which is typically used in patients receiving gemcitabine and carboplatin for metastatic triple-negative breast cancer.

Side effects associated with cancer CDK inhibitors

CDK inhibitors are increasingly being used as a therapeutic option for breast and other cancers due to their unique side effects. The most common is neutropenia, a temporary, dose-dependent low white blood cell count that increases infection risk. Other side effects include leukopenia, anemia, and thrombocytopenia. 

However, diarrhea, fatigue, nausea, and alopecia are mild and reversible with regular breaks. These factors restrict market growth, making it crucial to understand their side effects and drug interactions as they become increasingly popular in treating cancers.

Market Segment Analysis

The global cancer CDK inhibitors market is segmented based on drug type, cancer type, end-user, and region.

The Palbociclib from the drug type segment accounted for approximately 42.3% of the cancer CDK inhibitors  market share

The palbociclib from the drug type segment accounted for approximately 42.3%. Palbociclib (Ibrance) can be used in combination with aromatase inhibitors to treat advanced-stage or metastatic, hormone receptor-positive, HER2-negative breast cancer that has not been treated with hormonal therapy before. Three aromatase inhibitors are Arimidex, Aromasin, and Femara. Ibrance can also be used in combination with Faslodex to treat advanced-stage or metastatic, hormone receptor-positive, HER2-negative breast cancer that has grown after hormonal therapy.

For instance, in January 2023, Dr Reddy's Laboratories acquired the trademark rights for the breast cancer drug PRIMCYV from Pfizer Products India for Indian market use. PRIMCYV is a targetted therapy containing palbociclib, a first-in-class CDK 4/6 inhibitor, used in combination with an aromatase inhibitor for first-line treatment of adult patients with HR+, HER2- metastatic breast cancer.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like FDA approvals, and the rising prevalence of cancer in the U.S., which is the second-leading cause of death. Healthcare policies, high per capita spending, and advanced healthcare infrastructure.

For instance, in May 2024, Biotheryx, Inc., a biopharmaceutical company discovered and developed a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for BTX-9341, a novel cyclin-dependent kinase 4/6 (CDK4/6) bifunctional degrader. The Company plans to initiate the Phase 1 clinical trial in the second half of 2024 and enroll patients with HR+/HER2- breast cancer resistant to CDK4/6 inhibitor therapies.

Market Segmentation

By Drug Type

• Palbociclib
• Ribociclib 
• Abemaciclib
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Others

By Distribution channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the market include Pfizer Inc., Eli Lilly and Company, Novartis AG., Sanofi-Aventis, Merck & Co, Amgen, Bayer Pharmaceuticals, Piramal Life, G1 Therapeutics, AstraZeneca among others.

Key Developments

• In February 2024, Carrick Therapeutics dosed the first patient in its Phase 1b/2 clinical trial evaluating the combination of samuraciclib (CT7001), an oral CDK7 inhibitor, and vepdegestrant (ARV-471), an oral estrogen receptor degrader, jointly developed by Arvinas and Pfizer, in women with ER+, HER2- metastatic breast cancer who have previously received a CDK4/6 inhibitor.
• In November 2023, AstraZeneca's Truqap, a combination of Faslodex, was approved in the US for treating adult breast cancer patients with hormone receptor-positive, HER2-negative, locally advanced, or metastatic alterations. The FDA approved the treatment based on the results of the CAPItello-291 Phase III trial, which found Truqap in combination with Faslodex reduced the risk of disease progression or death by 50% compared to Faslodex alone in patients with PI3K/AKT pathway biomarker alterations.

Why Purchase the Report?

• To visualize the global cancer CDK inhibitors market segmentation based on drug type, cancer type, distribution channel, and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development. 
• excel data sheet with numerous data points of the cancer CDK inhibitors market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global cancer CDK inhibitors market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies